左旋多巴联合普拉克索对帕金森运动障碍患者的应用效果  

Effect of Levodopa Combined with Pramipexole Used in Patients with Parkinson's Disease-Induced Dyskinesia

作　　者：侯宇[1] 姜丽杰[1] 薛天宇 于敏[1] 娄伟[1] Hou Yu;Jiang Li-jie;Xue Tian-yu;Yu Min;Lou Wei(Department of Neurology,the Third People’s Hospital of Dalian,Dalian Liaoning 116033,China)

机构地区：[1]大连市第三人民医院神经内科,辽宁大连116033

出　　处：《中国合理用药探索》2019年第3期101-104,共4页Chinese Journal of Rational Drug Use

摘　　要：目的:探究左旋多巴联合普拉克索治疗帕金森运动障碍的效果。方法:选取2016年4月—2018年4月我院收治的帕金森(Pakinson disease,PD)运动障碍患者94例作为研究对象,按随机数字表法分为研究组和对照组,各47例。对照组给予左旋多巴(0.25 g,tid)治疗,研究组给予左旋多巴联合普拉克索(0.375 mg,bid,每七日增加一次剂量至最大疗效剂量,每日使用剂量不超过4.5 mg)治疗。比较两组临床疗效、用药安全性、治疗后非运动症状评分及生活质量。结果:研究组治疗总有效率为78.7%,高于对照组的59.6%,差异有统计学意义(P <0.05);两组不良反应发生率比较差异无统计学意义(P> 0.05);治疗后研究组睡眠疲劳、知觉幻觉、注意力记忆力、胃肠道症状、泌尿病症、性功能和其他评分均低于对照组,差异有统计学意义(P <0.05);治疗后2周、4周、12周和24周,研究组PD生活质量评分问卷(PDQ-39)评分均低于对照组,差异有统计学意义(P <0.05)。结论:左旋多巴联合普拉克索治疗PD的疗效显著,可缓解PD的运动障碍,降低非运动症状评分,且安全性高,值得推广。Objective:To explore the efficacy of levodopa combined with pramipexole in the treatment of Parkinson’s disease-induced dyskinesia.Methods:94 patients with Parkinson’s disease(PD)-induced dyskinesia admitted to our hospital from April 2016 to April 2018 were selected as subjects investigated and randomly divided into a study group and a control group,47 cases each.The patients in the control group were treated with levodopa(0.25 g,tid),while the patients in the study group were treated with levodopa combined with pramipexole(0.375 mg,bid,the dose was increased once every seven days to the maximum therapeutic dose,and the daily dose did not exceed 4.5 mg).The clinical efficacy,drug use safety,non-motor symptom scores after treatment and quality of life were compared between the two groups.Results:The total effective rate in the study group was 78.7%,which was higher than 59.6%in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the scores of sleep and fatigue,perception and hallucination,attention and memory,gastrointestinal symptoms,urinary diseases,sexual function and other scores in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After 2 weeks,4 weeks,12 weeks and 24 weeks of treatment,the scores of PD quality of life score questionnaire(PDQ-39)in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:Levodopa combined with pramipexole is significantly effective in the treatment of PD,which can alleviate PD-induced dyskinesia and reduce the score of non-motor symptoms,and is safe and worth popularizing.

关 键 词：左旋多巴 盐酸普拉克素 帕金森病 运动障碍 

分 类 号：R749[医药卫生—神经病学与精神病学]